Format

Send to

Choose Destination
Transfus Med. 2015 Apr;25(2):101-5. doi: 10.1111/tme.12181. Epub 2015 Mar 17.

Performance of Liaison XL automated immunoassay platform for blood-borne infection screening on hepatitis B, hepatitis C, HIV 1/2, HTLV 1/2 and Treponema pallidum serological markers.

Author information

1
Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Abstract

OBJECTIVES:

Aim of the study was to evaluate performance of a new fully automated platform, DiaSorin-LIAISON® XL (DiaSorin S.p.A, Vercelli, Italy), in blood donor screening, specifically for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), hepatitis C antibodies (anti-HCV), HIV p24 antigen, HIV antibodies, human T-lymphotropic virus types 1 and 2 (HTLV-1/2) and Treponema pallidum antibodies.

BACKGROUND:

In screening for such viral and bacteriological blood-borne infections, sensitivity and specificity are of utmost importance.

METHODS:

Sensitivity was evaluated using selected panels of samples previously analysed on the Abbott Architect immunoanalyser (Abbott Laboratories, Abbott Park, IL, USA)--the gold standard for this evaluation. These samples were confirmed positive for HBsAg, anti-HBc, anti-HCV, HIV Ag/Ab, anti-HTLV-1/2 and antibodies to T. pallidum, respectively. Specificity analysis was assessed by analysing blood donor samples previously run on the Architect platform and found non-reactive for each marker. A total of 1·100 donor samples (both new and regular donors) were tested. Previously, non-specific reactive samples were also run for every tested marker, as well as samples with autoimmune antibodies and antibodies to other infections.

RESULTS:

Three hundred seventy-eight samples positive for the tested markers (HBsAg n = 51, anti-HBc n = 52, anti-HCV n = 75, anti-Treponema n = 55, anti-HIV-1 n = 79, anti-HIV-2 n = 25, anti-HIV 1/2 n = 3, anti-HTLV-1 n = 28 anti-HTLV-2 n = 10) were tested and found positive, suggesting a high sensitivity. A number of 342-1100 negative blood donors (depending on marker) have been tested, with very good specificity for the markers tested, ranging between 99·5 and 100%, respectively.

CONCLUSIONS:

The LIAISON® XL platform demonstrated very high sensitivity for the markers tested and the specificity necessary to fulfil the stringent requirements for blood donor screening.

KEYWORDS:

Liaison XL; blood-borne infections; immunoassay; sensitivity; specificity

PMID:
25779614
DOI:
10.1111/tme.12181
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center